Kancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio’s phase III ready dutogliptin program and Kancera’s fractalkine program in phase II...
Read MoreKancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company’s strategic decision to focus on cardiovascular diseases.
Read MoreDevelopment resources are focused on cardiovascular diseases, initially with focus on treatment of STEMI based on the positive phase IIa results in the FRACTAL-study. Extensive market access research concerning the preliminary product positioning in STEMI verifies that the opportunities...
Read MoreKancera AB (publ) today announces that Robert Edfors is appointed as Chief Medical Officer (CMO) at Kancera, effective on November 1, 2024. Robert Edfors, specialist in cardiology and internal medicine, has up until now been the company’s Chief Scientific...
Read MoreIn connection with the interim report for the second quarter 2024, Kancera AB (publ) today provides a general operational update concerning its clinical development program and reports that: the phase IIa part in the KANDOVA study has been initiated...
Read MoreKancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.
Read MoreKancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567 in ovarian cancer in combination with carboplatin. The objective...
Read MoreIn connection with the upcoming Interim Report for the first quarter 2024, Kancera AB (publ) provides an operational update regarding KANDOVA, a combined phase Ib/IIa study of KAND567 in ovarian cancer, and reports that: The patient recruitment pace has...
Read MoreKancera AB (publ) today announces that Robert Edfors is appointed as new Chief Scientific Officer and Senior Vice President Clinical Development and that the management team is extended with two new positions.
Read MoreKancera AB (publ) today reports positive results from the clinical phase I study with KAND145 in healthy subjects and that the primary objectives of the study were met: KAND145 is safe and tolerable at maximum exposure when administered as...
Read More